(NASDAQ: TLX) Telix Pharmaceuticals's forecast annual revenue growth rate of 44.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 149.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.43%.
Telix Pharmaceuticals's revenue in 2025 is $492,583,018.On average, 2 Wall Street analysts forecast TLX's revenue for 2025 to be $271,476,619,937, with the lowest TLX revenue forecast at $267,501,766,677, and the highest TLX revenue forecast at $275,451,473,196. On average, 2 Wall Street analysts forecast TLX's revenue for 2026 to be $353,701,689,677, with the lowest TLX revenue forecast at $348,501,744,803, and the highest TLX revenue forecast at $358,901,634,552.
In 2027, TLX is forecast to generate $411,891,867,772 in revenue, with the lowest revenue forecast at $406,740,457,948 and the highest revenue forecast at $417,043,277,596.